We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 43 of 1320 for:    ALA

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02691923
Recruitment Status : Recruiting
First Posted : February 25, 2016
Last Update Posted : February 13, 2018
Sponsor:
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
Carl Zeiss Meditec, Inc.
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:

This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy sampling during the procedure.

Subjects will include those people with operable brain tumor with first-time presumed pre-surgical diagnosis of high-grade glioma or low-grade glioma.


Condition or disease Intervention/treatment Phase
Brain Cancer Drug: Fluorescein Drug: Fluorescein + ALA Phase 2

Detailed Description:

Consenting subjects who have met inclusion and exclusion criteria will be enrolled to receive either fluorescein+ALA or fluorescein alone. HGG patients will be randomized on a 2 to 1 basis to receive either both fluorescein and ALA or fluorescein alone, and LGG patients will be randomized on a 1 to 1 basis.

This study is a diagnostic trial of fluorescein fluorescence as an intraoperative imaging biomarker during open cranial surgery for tumor resection of first-time (preoperatively) presumed high or low grade glioma. Subjects participate in a "one-time" event/visit (i.e, surgery) as part of this protocol. Images and data from the patient's pre- and post-operative MR scans are used for analysis in the study, but these acquisitions are part of the patient's standard-of-care, would occur independently of whether the participant is enrolled; and thus, are not considered to be research study visits. No post-surgical follow-up visit is part of the protocol data collection or analysis. Patients are monitored for possible adverse events through the routine follow-up under the care of the operating surgeon involved in the study procedures, post-operatively and subsequently through the medical record. Hence, this information is already being collected as part of standard-of-care and is available for adverse event surveillance. Patients receiving ALA who present with abnormally elevated LFTs beyond the peri-operative observation period are monitored on a regular basis until resolution and this blood testing is considered to be part of the study.

Administration of study drug:

Patients enrolled in the fluorescein+ALA arm will be administered orally 5-ALA (DUSA Pharmaceuticals, Tarrytown, NY) at 20 mg/kg body weight, dissolved in 100 ml of water, approximately 3 hours prior to the induction of anesthesia.

For patients receiving only fluorescein, the operating surgeon will request bolus injection (at a dose of 5 mg/kg) approximately 30 minutes prior to the start of tumor resection. For especially long cases (e.g., > 4 h) or if fluorescein fluorescence dissipates substantially during the course of the procedure, a second bolus injection may occur later in the case.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology
Study Start Date : March 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Fluorescein
Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
Drug: Fluorescein
Other Name: Fluorescite
Experimental: Fluorescein + ALA

Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.

ALA administered orally at 20mg/kg approximately 3 hours before surgery.

Drug: Fluorescein + ALA
Other Name: Flourescein = Fluorescite; ALA = 5-Aminolevulinic Acid



Primary Outcome Measures :
  1. Fluorescein performance as an intraoperative biomarker for tumor tissue will be reported. [ Time Frame: 24 months ]
    The predictive performance of fluorescein fluorescence as an intraoperative imaging biomarker of tumor during surgery in patients with a clinical diagnosis of high grade glioma (HGG) and patients with a clinical diagnosis of low grade glioma (LGG) will be measured. Fluorescence will be measured both quantitatively via an intraoperative probe and visually by the neurosurgeon through the operating microscope. Endpoints will be assessed separately for HGG and LGG groups.


Secondary Outcome Measures :
  1. Fluorescein performance as visualized and measured with an intraoperative probe will be reported [ Time Frame: 24 months ]
    The performance of fluorescein as visualized by the neurosurgeon and measured quantitatively with an intraoperative probe will be analyzed to the contrast-enhancement on coregistered preoperative MR scans in patients with a clinical diagnosis of high grade glioma.

  2. Fluorescein versus fluorescein + ALA performance will be reported in patients in patients with 2 different types of tumors [ Time Frame: 24 months ]
    The performance of fluorescein versus fluorescein + ALA as visualized by the neurosurgeon and measured quantitatively with an intra-operative probe will be analyzed in patients with a clinical diagnosis of either high grade glioma (HGG) or low grade glioma (LGG).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Preoperative diagnosis of either presumed first-time low or high grade glioma (astrocytoma, oligodendroglioma, mixed oligo-astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme).
  2. Tumor judged to be suitable for open cranial resection based on preoperative imaging studies.
  3. Valid informed consent by subject or subject's LAR.
  4. No serious associated psychiatric illnesses.
  5. Age ≥ 21 years old.

Exclusion Criteria:

  1. Pregnant women or women who are breast feeding.
  2. History of hypersensitivity to fluorescein.
  3. History of cutaneous photosensitivity, porphyria, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis.
  4. History of liver disease within the last 12 months.
  5. Elevated LFTs (AST, ALT, ALP or bilirubin levels greater than 2.5 times the normal limit) from laboratory tests conducted within 30 days prior to surgery.
  6. Serum creatinine in excess of 180µmol/L (2.04 md/dL) within 30 days prior to surgery.
  7. Inability to comply with the photosensitivity precautions associated with the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02691923


Contacts
Contact: Margaret A Notestine, CCRC Margaret.A.Notestine@hitchcock.org
Contact: Neurology and Neurosurgery Research NeurologyResearch@hitchcock.org

Locations
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Neurology Research       NeurologyResearch@hitchcock.org   
Contact: Margaret A. Notestine       Margaret.A.Notestine@hitchcock.org   
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
National Institute of Neurological Disorders and Stroke (NINDS)
Carl Zeiss Meditec, Inc.
Investigators
Principal Investigator: David W Roberts, MD Dartmouth-Hitchcock Medical Center

Publications:
Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT02691923     History of Changes
Other Study ID Numbers: D12090
First Posted: February 25, 2016    Key Record Dates
Last Update Posted: February 13, 2018
Last Verified: February 2018

Keywords provided by Dartmouth-Hitchcock Medical Center:
High Grade Glioma
Low Grade Glioma
Brain Tumor

Additional relevant MeSH terms:
Aminolevulinic Acid
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Photosensitizing Agents
Dermatologic Agents